Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

CHAPEL HILL, N.C., Jan. 12, 2011 /PRNewswire/ -- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12 in Washington D.C.  

Solithromycin is a clinical-stage fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, non-bacterial pathogens such as Plasmodium falciparum and a variety of bio-defense pathogens including Bacillus anthracis, Yersinia pestis, Burkholderia mallei and Francisella tularensis.  Phase 1 clinical studies with the oral formulation have shown excellent safety and tolerability and a pharmacokinetic profile that will enable once-daily dosing.  The oral formulation is undergoing a Phase 2 clinical trial in patients with community-acquired bacterial pneumonia (CABP).  An intravenous (IV) formulation of solithromycin is undergoing a safety and tolerability evaluation in a Phase 1 single and multiple dose escalation trial in healthy volunteers.  An oral pediatric suspension is also under development.

The presentation, delivered on January 12 by Jennifer Schranz, M.D., vice president of clinical affairs at Cempra Pharmaceuticals, described the potential utility of solithromycin as a bio-defense agent due to its broad antimicrobial spectrum, safety and tolerability, once-daily dosing, high tissue penetration, intracellular accumulation, and compound stability.  Data from mouse models were presented on the activity of once-daily solithromycin compared to an optimal dosing regimen of ciprofloxacin against B. anthracis and gentamicin against F. tularensis.  Solithromycin demonstrated activity comparable to c
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
3. Savient Pharmaceuticals Provides Business Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... June 1, 2015  Berg, a biopharmaceutical company committed ... presented clinical research from its trials using its cancer ... preclinical data on triple negative breast cancer, at the ... of Clinical Oncology (ASCO), May 29 – June 2 ... BPM 31510 is one of the first cancer drugs ...
(Date:6/1/2015)... , June 1, 2015  Albany ... announced today that it has signed a ... to co-market their structure-based drug discovery services ... part of the three-year agreement, AMRI gains ... expertise and capabilities. HarkerBIO,s customers will be ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... Alternative will be Centerpiece to Expansion of ... Radiation Oncology ... ARAY ), a global leader in the field of radiosurgery,today ... CyberKnife(R) Robotic Radiosurgery System to further expand treatment,offerings for its ...
... Corn Borer Technology Offers Greater Control of Common, ... Southern U.S. Growers, ST. LOUIS, July 24 ... deregulated MON 89034, a new insect,protection technology from ... above ground insect control technology will be stacked ...
... United,Therapeutics Corporation (Nasdaq: UTHR ) announced ... financial results before the open of market,on Thursday, ... a half-hour teleconference on Thursday,July 31, 2008, at ... dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A rebroadcast ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4New Insect Protection Technology From Monsanto Company Deregulated by USDA 2New Insect Protection Technology From Monsanto Company Deregulated by USDA 3
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... remains a goal for governments around the world, nuclear ... as recognised at the 2010 nuclear security summit in ... prevent the proliferation of nuclear weapons, but they are ... role science in this field. A new European nuclear ...
... Researchers from the Georgia Institute of Technology have ... of people worldwide from dying of pneumonia each year. ... is a solution to the problem of diagnosing pneumonia, ... for Disease Control and Prevention (CDC). Pneumonia, an ...
... University of Arizona College of Engineering researcher and his ... will be featured in a segment of an upcoming ... will be featured on the episode premiering Thursday night, ... KUAT Channel 6. "WaveLengths" is a quarterly science program ...
Cached Biology News:Enhancing nuclear security: Training and international collaboration 2A better way to diagnose pneumonia 2A better way to diagnose pneumonia 3Planetary exploration robots to be featured on science program 'WaveLengths' 2
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: